GHP Funds


SVP I, the debut fund for the firm, closed in December 2002 and invested with four highly successful leveraged buyout funds. SVP I is diversified by sector and geography.

Learn More

SVP II is a leveraged buyout fund of funds which closed in December 2006. SVP II represents a continuation of the successful strategy utilized by the predecessor fund, primarily investing with large, top tier LBO and growth equity firms. SVP II is diversified by sector and geography.

Learn More

SVP Real Estate I, LP ("SVP RE I"), closed in February 2008, is a private real estate fund of funds. As with SVP I & II, SVP RE I received allocations with historically successful, highly sought after underlying fund managers who pursue compelling investment strategies. The fund is diversified by sector (Office, Hotel, Industrial/Warehouse, Retail and Residential) and geography (U.S., Europe, and Asia/Pacific).

Learn More

The GHP Credit Opportunity Fund (“GHP COF”) is a fund of alternative credit and distressed debt funds that is being raised and invested to pursue two specific investment themes: (1) the de-leveraging of European Banks, and (2) the potential for a distressed cycle in U.S. High Yield Credit. GHP COF will pursue complex liquid and illiquid credit opportunities in the U.S. and Europe.

Learn More

GHP Library

MedReleaf Australia Commences Commercial Operations

Indica Industries Pty Ltd, the partner of Canadian licensed producer MedReleaf (TSX: LEAF) (OTC: MEDFF) that is operating as MedReleaf Australia, has commenced commercial operations. The company, which received its cultivation and production license in November, will be initially importing oils and capsules that are available for delivery in the first quarter of 2018 to hospitals and pharmacies.

We’re delighted to have been granted Australian medicinal cannabis licenses and look forward to teaming with  MedReleaf Corp to introduce their scientific and operational rigour to the Australian medical cannabis industry.

Russell Harding, CEO of Indica Industries Pty Ltd

The company expects to complete an initial facility of 86K sq. ft. in 2018 and to almost triple it over time. MedReleaf owns 10% of the company.

MedReleaf Corp is focused on international expansion in countries with a federal legal framework for cannabis. Australia is an attractive market with a population about two-thirds the size of Canada that focuses on medicinal applications.

Neil Closner, CEO of MedReleaf

Providing our expertise to local partners allows us to participate in a greater number of international markets in a capital efficient way.

In addition to the cultivation and production license that it holds, MedReleaf Australia has applied for a manufacturing license with the Office of Drug Control.

Leave a Comment